Search Follow us


Orexo reported an operational quarter in line with guidance. Total revenues of SEK139.7m in Q118 represented an increase of about 10% vs Q117. Orexo’s key product, Zubsolv, saw revenues in the US increase by 15% vs Q117 to SEK131.1m. Improved working capital management and cost of goods sold (CoGS) efficiencies promise to deliver another full year of profitability in FY18 and beyond. We have rebuilt our model and our new valuation is SEK2.2bn or SEK63 per share.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs